Fecal Fat - Cholesterol Test

Cholesterol in fecal fat represents the body’s main route for getting rid of excess cholesterol. It includes cholesterol that was not absorbed from food, cholesterol converted into bile acids, and cholesterol secreted directly into the intestine. This process is central to maintaining cholesterol balance and protecting against cardiovascular disease.

There are two main pathways by which cholesterol reaches the feces. The first is the biliary pathway, where the liver secretes cholesterol and bile acids into bile, which then enters the intestine. The second is the transintestinal cholesterol excretion (TICE) pathway, a more recently recognized mechanism in which intestinal cells (enterocytes) directly transfer cholesterol from the bloodstream into the gut lumen. In healthy humans, TICE may account for up to one-third of all cholesterol lost in feces. Unlike the biliary route, TICE does not rely on bile flow, offering an alternative pathway for cholesterol clearance that could be enhanced therapeutically.

Both routes support reverse cholesterol transport (RCT), the body’s system for moving cholesterol out of peripheral tissues, like artery walls, back to the liver and intestine for disposal. Efficient RCT is linked to protection from atherosclerosis, the buildup of plaque in arteries. Higher rates of fecal cholesterol excretion have been associated with lower carotid intima-media thickness, a marker of arterial aging and cardiovascular risk.

Diet and medication can strongly influence these pathways. Diets higher in unsaturated fats, such as those from olive oil, nuts, and fish, consistently increase fecal cholesterol excretion and lower blood cholesterol compared to diets high in saturated fats. This occurs because unsaturated fats promote the conversion of cholesterol into bile acids and enhance its loss through the stool. Similarly, certain compounds like plant sterols and ezetimibe act by blocking intestinal cholesterol absorption and stimulating TICE, making them effective tools for lowering LDL cholesterol levels. Emerging evidence suggests that liver X receptor (LXR) agonists could also amplify cholesterol excretion through TICE, though their clinical use remains experimental.

Even seemingly unrelated factors, such as calcium intake, can increase fecal cholesterol loss by binding fatty acids and sterols in the gut. This may partly explain why diets rich in dairy calcium or supplemented calcium can modestly improve cholesterol profiles in some people.

Clinically, fecal cholesterol is measured as part of the fecal neutral sterol fraction, sometimes alongside bile acids, using specialized chemical or isotopic techniques. While this is mainly done in research settings rather than routine clinical care, it provides valuable insight into cholesterol metabolism and the effectiveness of dietary or drug interventions.